



Dr. Sweatt and his team want to ensure that our patients and community receive the best care possible. As such, we always advocate for prevention and would like to share a silver lining with our beloved community in regards to COVID 19. Please read an excerpt of an article from the American Journal of Gastroenterology below.

As a reminder:

Dr. Sweatt and Jackie Siver are still seeing patients virtually via *Telehealth*. If you would like to make an appointment or have an upcoming appointment and need help on how to access the portal, please call our office at (979)297-4033. We are in the office Monday - Thursday from 8:00 - 5:00 & Friday from 8:00 - 1:00.





Famotidine (Pepcid) in treating COVID19

Famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19.

Among the many therapeutic alternatives that are currently being tested for treating patients with coronavirus (COVID-19) is the use of the histamine-2 receptor antagonist, famotidine. Following an early anecdotal report from Wuhan, China, that suggested that famotidine use was **commonly observed in COVID-19 survivors**, a retrospective cohort study of 1,620 hospitalized patients with COVID-19 demonstrated that patients receiving famotidine had statistically significant **reductions in both in-hospital death and a combined death and intubation**. More recently, a small case series of non-hospitalized patients with COVID-19 treated with high-dose oral famotidine documented a marked improvement in symptoms in all cases shortly after starting the drug...

Read the full article online here: American Journal of Gastroenterology

We hope this is good news for all and will keep you posted on the latest updates. In health,

Dr. William Sweatt

(979)297-4033

office@tummydoc.net Latest update as of 4-5-20